Co-Authors
This is a "connection" page, showing publications co-authored by Fu-Sheng Wang and Markus Maeurer.
Connection Strength
1.528
-
Host-directed therapies for COVID-19. Curr Opin Pulm Med. 2021 05 01; 27(3):205-209.
Score: 0.236
-
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021 02 10; 6(1):58.
Score: 0.232
-
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020 08 27; 5(1):172.
Score: 0.225
-
Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020 09; 21(9):1107-1118.
Score: 0.224
-
Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. Int J Infect Dis. 2020 Sep; 98:454-459.
Score: 0.223
-
Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis. 2020 Jul; 96:431-439.
Score: 0.221
-
Immune responses during COVID-19 infection. Oncoimmunology. 2020 08 25; 9(1):1807836.
Score: 0.056
-
Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020 07 08; 11(1):3410.
Score: 0.056
-
Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ. 2020 11; 27(11):3196-3207.
Score: 0.055